Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.

A comparison of the effects of the 6-(2-chloro-6-fluorobenzyl)-2-(alkylthio)pyrimidin-4(3H)-ones (2-Cl-6-F-S-DABOs) 7-12 and the related 6-(2,6-difluorobenzyl) counterparts 13-15 in HIV-1 infected cells and in the HIV-1 reverse transcriptase (RT) assays is here described. The new 2-Cl-6-F-S-DABOs showed up to picomolar activity against wt HIV-1. Against clinically relevant HIV-1 mutants and in enzyme assays, the simultaneous C5(methyl)/C6(methyl/ethyl) substitution in the 2-Cl-6-F- and 2,6-F2-benzyl series furnished compounds with the highest, wide-spectrum inhibitory activity against HIV-1. Three representative 2-Cl-6-F-S-DABOs carrying two (9c, 10c) or one (10a) stereogenic centers were resolved into their individual stereoisomers and showed a significant diastereo- and enantioselectivity in HIV-1 inhibition, the highest antiviral activity well correlating with the R absolute configuration to the stereogenic center of the C6-benzylic position in both cellular and enzymatic tests. Application of previously reported COMBINEr protocol on 9c and 10c confirmed the influence of the stereogenic centers on their binding modes in the HIV-1 RT.

[1]  E. Crespan,et al.  Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity. , 2005, Journal of medicinal chemistry.

[2]  A. Mai,et al.  5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile. , 2008, Journal of medicinal chemistry.

[3]  A. Mai,et al.  Structure—Activity Relationship Studies on New DABOs: Effect of Substitutions at Pyrimidine C-5 and C-6 Positions on Anti-HIV-1 Activity , 2001, Antiviral chemistry & chemotherapy.

[4]  A. Mai,et al.  Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors. , 2011, Journal of medicinal chemistry.

[5]  A. Mai,et al.  Synthesis and Antiviral Activity of New 3,4-Dihydro-2-Alkoxy-6-Benzyl-4-Oxopyrimidines (DABOs), Specific Inhibitors of Human Immunodeficiency Virus Type 1 , 1995 .

[6]  M. Artico.  Selected non-nucleoside reverse transcriptase inhibitors (NNRTIs): the DABOs family , 2002 .

[7]  J. Ponder,et al.  An efficient newton‐like method for molecular mechanics energy minimization of large molecules , 1987 .

[8]  A. Mai,et al.  5-Alkyl-2-alkylamino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new series of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family. , 2005, Bioorganic & medicinal chemistry.

[9]  L. Waters,et al.  Non‐nucleoside reverse transcriptase inhibitors: a review , 2007, International journal of clinical practice.

[10]  D. Jayaweera,et al.  New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data , 2012, Expert opinion on pharmacotherapy.

[11]  M. Botta,et al.  Synthesis, antimicrobial and antiviral activities of isotrimethoprim and some related derivatives , 1992 .

[12]  C. Pannecouque,et al.  Synthesis and Biological Evaluation of 6‐Substituted 5‐Alkyl‐2‐(phenylaminocarbonylmethylthio)pyrimidin‐4(3H)‐ones as Potent HIV‐1 NNRTIs , 2011, ChemMedChem.

[13]  Garland R. Marshall,et al.  VALIDATE: A New Method for the Receptor-Based Prediction of Binding Affinities of Novel Ligands , 1996 .

[14]  A. Mai,et al.  Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines. , 1995, Journal of medicinal chemistry.

[15]  A. Mai,et al.  Chiral HPLC separation and absolute configuration of novel S-DABO derivatives. , 2009, Chirality.

[16]  A. Mai,et al.  3,4-Dihydro-2-Alkoxy-6-Benzyl-4-Oxopyrimidines (DABOs): A New Class of Specific Inhibitors of Human Immunodeficiency Virus Type 1 , 1993 .

[17]  A. Mai,et al.  Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains. , 2007, Journal of medicinal chemistry.

[18]  A. Mai,et al.  Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series. , 1997, Journal of medicinal chemistry.

[19]  E. De Clercq,et al.  Dihydro-alkoxyl-benzyl-oxopyrimidine derivatives (DABOs) as non-nucleoside reverse transcriptase inhibitors: an update review (2001-2011). , 2012, Current medicinal chemistry.

[20]  Garland R. Marshall,et al.  Comprehensive model of wild-type and mutant HIV-1 reverse transciptases , 2012, Journal of Computer-Aided Molecular Design.

[21]  E. Novellino,et al.  5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives. , 1999, Journal of medicinal chemistry.

[22]  A. Mai,et al.  6-(Arylmethyl)pyrimidin-4(3H)-ones: anthology and prospects of highly efficient anti-HIV agents , 2012, Russian Chemical Bulletin.

[23]  Ira Musmuca,et al.  2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies. , 2012, Journal of medicinal chemistry.

[24]  A. Mai,et al.  Chiral resolution and molecular modeling investigation of rac-2-cyclopentylthio-6-[1-(2,6-difluorophenyl)ethyl]-3,4-dihydro-5-methylpyrimidin-4(3H)-one (MC-1047), a potent anti-HIV-1 reverse transcriptase agent of the DABO class. , 2001, Chirality.

[25]  A. Mai,et al.  Analytical and semipreparative high performance liquid chromatography separation of stereoisomers of novel 3,4-dihydropyrimidin-4(3H)-one derivatives on the immobilised amylose-based Chiralpak IA chiral stationary phase. , 2006, Journal of separation science.

[26]  B. Clotet,et al.  ADS-J1 Inhibits HIV-1 Entry by Interacting with gp120 and Does Not Block Fusion-Active gp41 Core Formation , 2010, Antimicrobial Agents and Chemotherapy.

[27]  U Hübscher,et al.  Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. , 1997, Journal of molecular biology.

[28]  Iris Usach,et al.  Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability , 2013, Journal of the International AIDS Society.

[29]  Gianluca Sbardella,et al.  Slow‐, Tight‐Binding HIV‐1 Reverse Transcriptase Non‐Nucleoside Inhibitors Highly Active against Drug‐Resistant Mutants , 2007, ChemMedChem.

[30]  Eduardo Pauls,et al.  Anti-HIV Activity and Resistance Profile of the CXC Chemokine Receptor 4 Antagonist POL3026 , 2008, Molecular Pharmacology.

[31]  A. Mai,et al.  6-[1-(2,6-difluorophenyl)ethyl]pyrimidinones antagonize cell proliferation and induce cell differentiation by inhibiting (a nontelomeric) endogenous reverse transcriptase. , 2005, Journal of medicinal chemistry.

[32]  B. Clotet,et al.  Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level. , 2011, Journal of medicinal chemistry.

[33]  B. Clotet,et al.  HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro , 2008, AIDS.

[34]  Silvio Massa,et al.  Synthesis, biological evaluation, and binding mode of novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles targeted at the HIV-1 reverse transcriptase. , 2002, Journal of medicinal chemistry.

[35]  Silvio Massa,et al.  Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. , 2004, Journal of medicinal chemistry.

[36]  E Novellino,et al.  Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2001, Journal of medicinal chemistry.

[37]  Antonello Mai,et al.  Substrate‐Induced Stable Enzyme–Inhibitor Complex Formation Allows Tight Binding of Novel 2‐Aminopyrimidin‐4(3H)‐ones to Drug‐Resistant HIV‐1 Reverse Transcriptase Mutants , 2008, ChemMedChem.

[38]  G. Maga,et al.  Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants. , 2007, Journal of medicinal chemistry.

[39]  Chris Morley,et al.  Pybel: a Python wrapper for the OpenBabel cheminformatics toolkit , 2008, Chemistry Central journal.